Skip to main content
Equibles
ANIP logo

ANIP · Ani Pharmaceuticals Inc · Metrics

Track ANIP — free

Use ANIP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ANIP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$72.61 -1.14 (-1.55%) At close · Oct 23
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$1.67B
Shares
22.97M
Volume · Oct 23 318.61K Avg daily vol (3M) 382.32K

ANIP metrics

91 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$72.61
Market cap
$1.67B

Price action

20 metrics
Price change (1W)
+0.4%
Price change (30D)
-1.9%
Price change (3M)
-6.5%
Price change (6M)
-7.7%
Price change (YTD)
-8.0%
Price change (1Y)
-23.5%
Trailing year
Price change (5Y)
+97.0%
52-week high
$94.90
52-week low
$70.16
Change from 52-week high
-23.5%
Change from 52-week low
+3.5%
Annualized volatility
31.5%
Annualized volatility (3M)
29.7%
Beta
0.3
RSI (14D)
48.6
Price vs SMA 50
-1.1%
Price vs SMA 200
-6.8%
Avg volume (3M)
382,322
Relative volume
0.8
Average dollar volume
$28.61M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
22.97M

Valuation

12 metrics
P / E (TTM)
15.8
Trailing earnings · reciprocal yield 6.3%
PEG ratio
0.1
EV / revenue
1.6×
reciprocal yield 60.8%
EV / EBITDA
6.8×
reciprocal yield 14.7%
EV / EBIT
10.7×
reciprocal yield 9.3%
P / sales
1.7×
reciprocal yield 58.7%
P / book
2.8
reciprocal yield 35.8%
FCF yield
10.4%
TTM · current market cap
Buyback yield
1.3%
P / FCF
9.6
reciprocal yield 10.4%
P / operating cash flow
8.8
reciprocal yield 11.4%
Earnings yield
6.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
0.3%
Shareholder yield
1.4%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-07

Profitability

9 metrics
Gross margin
—
Operating margin
15.4%
Trailing 12 months
Net margin
11.1%
Gross profit (TTM)
$127.88M
Operating profit (TTM)
$150.35M
Net income (TTM)
$108.31M
Trailing 12 months
Diluted EPS (TTM)
$4.60
FCF margin
17.7%
Effective tax rate
24.0%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
$10.66
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$24.04

Growth

11 metrics
Revenue growth YoY
+25.9%
Year over year
Net income growth YoY
+189.1%
Revenue (TTM)
$978.38M
Trailing 12 months
EPS growth YoY
+191.7%
Shares change YoY
+7.9%
Year over year · more shares
Revenue CAGR (3Y)
+40.8%
Revenue CAGR (5Y)
+33.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
+79.8%

Quality

14 metrics
Return on equity
18.1%
Return on assets
7.2%
Debt / equity
0.5
Current ratio
2.9
EBITDA (TTM)
$236.16M
Free cash flow (TTM)
$172.99M
Quick ratio
2.4
Interest coverage
—
Net debt / EBITDA
-0.2
Return on invested capital
21.2%
Trailing 12 months
Net cash
$58.73M
Latest balance sheet
Cash & equivalents
$360.21M
Total assets
$1.49B
Total debt
$301.48M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$189.47M
Capital expenditures (TTM)
$16.48M
R&D (TTM)
$49.91M
SG&A (TTM)
$324.76M
Stock compensation (TTM)
$41.06M
R&D / revenue
5.1%
Stock compensation / revenue
4.2%

Ownership (13F)

9 metrics
13F filers
308
13F filer change QoQ
+26
Institutional ownership
101.0%
Conviction holders (share of 13F filers)
1.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-5.6%
Holder tenure
12.8
Price vs estimated holder cost
+12.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
22.3%

Short interest

3 metrics
Short interest
15.2%
Latest settlement · 7.2 days to cover
Days to cover
7.2d
Short-squeeze score
82 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$2.25M
Insider-sentiment score
45 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1023024 CUSIP 00182C103 13F (30d) 39 filings 39 filers Visit website Investor relations